by IgNS | Mar 18, 2020 | Latest News
Coronavirus vaccine trial administers first doses to participants A Phase 1 clinical trial evaluating an investigational vaccine designed to protect against coronavirus disease 2019 (COVID-19) has begun at Kaiser Permanente Washington Health Research Institute...
by IgNS | Mar 17, 2020 | Latest News
Dear Colleagues, IgNS is closely following the developments regarding the COVID-19 pandemic. This is a rapidly evolving situation, with information and guidance updated on an ongoing basis to reflect the most recent recommendations. Please check for updates from the...
by IgNS | Mar 14, 2020 | Latest News
COVID-19 Update IgNS thanks all healthcare professionals and service providers, first responders, government agencies, and the healthcare industry who are working tirelessly in the face of the COVID-19 pandemic. Roche receives emergency approval for COVID-19...
by IgNS | Feb 27, 2020 | Latest News
Novel Coronavirus (COVID-19 or SARS-CoV-2) and Plasma Safety IgNS Statement Regarding the Novel Coronavirus (COVID-19 or SARS-CoV-2) The recent outbreak of the 2019 Novel Coronavirus (COVID-19 or SARS-CoV-2) has raised awareness around the safety of plasma...
by IgNS | Sep 24, 2019 | Latest News
On Sept. 23, the Healthcare Quality and Safety team at USP issued a letter announcing that it would delay the planned Dec. 1 implementation of three of its chapters: the revised <795> Pharmaceutical Compounding—Nonsterile Preparations and <797>...
by IgNS | Jul 17, 2019 | Latest News
Examining the Application of Immunoglobulin in Multiple Disease States: A Review of Evidence Activity Overview: The administration of immunoglobulin (Ig) has become common practice in the treatment of patients with immunodeficiencies, and, more recently, in other...
